Showing results (371-380 of 3,348) with videos related to
Sort By:
Pageof 335
Pharmacoeconomics|March 8, 1997
Cost-minimisation analysis of sequential treatment with ofloxacin or ciprofloxacin in hospitalised patientsE Salewski, H P Bassaris, S Calangu, et al.Pharmacoeconomics|June 6, 1997
Economics of thromboprophylaxis in total hip replacement surgeryJ Harrison, D J Warwick, J CoastPharmacoeconomics|July 6, 1997
An economic analysis of the Survival and Ventricular Enlargement (SAVE) Study. Application to the United KingdomS Hummel, J Piercy, R Wright, et al.Pharmacoeconomics|August 5, 1997
Why training is the key to successful guideline implementationA D Paltiel, P J NeumannPharmacoeconomics|August 5, 1997
Dornase alfa. A review of pharmacoeconomic and quality-of-life aspects of its use in cystic fibrosisK L Goa, H LambPharmacoeconomics|August 5, 1996
Cost saving of 5-day therapy with cefpodoxime proxetil versus standard 10-day beta-lactam therapy for recurrent pharyngotonsillitis in adults. A prospective general practice studyA Pelc, H Portier, P Gehanno, et al.Pharmacoeconomics|September 4, 1996
Health-related quality of life in inflammatory bowel diseaseG M Eisen, R G FarmerPharmacoeconomics|May 7, 1997
Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphomaG Dranitsaris, C Altmayer, I QuirtPharmacoeconomics|October 4, 1997
Current issues in German healthcareJ M Graf von der Schulenburg, A UberPharmacoeconomics|October 4, 1997
Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosisG M Ginsberg, B LevPageof 335